Deep Track Capital, LP — SEC Form 4 filings
SEC reporting owner CIK 1856083. 7 Form 4 filings on record with FilingPulse; latest filed 2026-08-10.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-05-13 to 2026-08-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 2,666,666 shares, $39,999,990 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 2,121,137 shares, $22,451,228 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: purchase of 2,000,000 shares @ $15.00 ($30,000,000) in LB PHARMACEUTICALS INC, filed 2025-09-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | 10% owner | 3 | 2 legs · 2,666,666 sh · $39,999,990 | — | 5 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) | 10% owner | 2 | — | 2 legs · 2,065,137 sh · $22,351,598 | 1 |
| NEKTAR THERAPEUTICS (NKTR) | 10% owner | 1 | — | 1 leg · 56,000 sh · $99,630 | — |
| Attovia Therapeutics, Inc. (ATTO) | 10% owner | 1 | — | — | 2 |
Form 4 filings — Deep Track Capital, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-10 | 4 | Attovia Therapeutics, Inc. (ATTO) jointly with Deep Track Biotechnology Master Fund, Ltd., KROIN DAVID | Conversion (C): 1,957,138 · Conversion (C): 18,181,818 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | LB PHARMACEUTICALS INC (LBRX) jointly with Deep Track Biotechnology Master Fund, Ltd., KROIN DAVID | Purchase (P): 286,205 (derivative) @ $34.94 | EDGAR |
| 2026-02-11 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) jointly with Deep Track Biotechnology Master Fund, Ltd., KROIN DAVID | Code (U): 15,726,349 | EDGAR |
| 2026-02-10 | 4 | LB PHARMACEUTICALS INC (LBRX) jointly with Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, KROIN DAVID | Purchase (P): 378,444 (derivative) @ $21.17 · Purchase (P): 93,925 (derivative) @ $21.17 | EDGAR |
| 2025-09-16 | 4 | LB PHARMACEUTICALS INC (LBRX) jointly with Deep Track Biotechnology Master Fund, Ltd., KROIN DAVID | Conversion (C): 686,138 · Purchase (P): 2,000,000 @ $15 · Purchase (P): 666,666 @ $15 · Conversion (C): 16,666,667 (derivative) | EDGAR |
| 2025-08-22 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) jointly with Deep Track Biotechnology Master Fund, Ltd., KROIN DAVID | Sale (S): 1,094,994 @ $11.03 · Sale (S): 970,143 @ $10.59 | EDGAR |
| 2024-05-13 | 4 | NEKTAR THERAPEUTICS (NKTR) jointly with Deep Track Biotechnology Master Fund, Ltd., KROIN DAVID | Sale (S): 56,000 @ $1.78 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1856083 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →